DOGE’s $1 Federal Spending Limit Is Straight Out of the Twitter Playbook

Katie Drummond: Okay We were saying a lot in the wired in the past few months, remove as fast and break the things. We’re going to take a short break when we come back, what to read in your ward today.

Welcome back Uncanny valleyThe I am Katie Drummond, Wired Global Editorial Director. I joined the Wired Business and Industrial Director Joa Shifer. Now Joe, before I give up on you, tell our audience what they should read, we must read at Ward.com today, except the stories we talked about in this episode.

Joey Shifer: Okay I hope I had a beautiful, joyful, enthusiastic story to talk to you but I have a more doom and dark story and it is by it-

Katie Drummond: Oh-shocks

Joey Shifer: I know This is Caroline Husquins, who is a freelancer for us and in reality we have just announced that he is joining the business desk. So exciting. He is incredible. He is very good. I am very excited. And he wrote a piece that we published about the cut of Trump and Elon masks in the FDA yesterday, so another administration that experienced the fatal budget and stuffing cuts has already risked the development of the drug. And he got it from dozens of SEC filing of pharmaceutical companies.

Katie Drummond: So in that SEC filing and what you and Emily reported about this credit card frost yesterday, it seems that we see federal agencies stop here in some way.

Joey Shifer: Yes I mean it’s interesting because drug companies, drug companies are not even saying, “FDA is not approved our drugs, and so these drugs cannot come to market.” They say that this company was already running so slowly through the design because the bettings are very, very much when you are talking about drugs and drugs. And so cut the stuffing, cut the budget. The anxiety is that it will stop. And if you are a pharmaceutical company that has already been approved or decided in a lot of time, strength and establishment, the money behind the development of a new drug that you are not sure will get the FDA approval, Suddenly you are going to see less than that, we will pay only the existing product pipeline. And this has a really serious impact for people who may need this new therapy.

Katie Drummond: Joe, thank you for the joy that you have brought in our show today. Thank you for joining me. In fact, though, so grateful for your report and team report.

Joey Shifer: Thank you so much for having me.

Katie Drummond: This is our show for today. We will link to all the stories we talked about today on show notes. Check out Thursday’s episode Uncanny valleyAll of which is about the naturalist movement of Silicon Valley. If you like what you’ve heard today, be sure to follow our show and rate it on your favorite podcast app. If you want to contact us to show the question, comment or suggestion, write to us uncanavalley@wired.comThe

Macro Sound mixed my red episode on Macro Sound. Jack Lummas is our studio engineer. Jordan Bell is our executive maker, Chris Banon, the head of the global audio of Condie Nust. And I am Katie Drummond, Wired Global Editorial Director.

Departure